Axsome Therapeutics Shares Data from Multiple Programs at Sleep Europe 2024

Axsome Therapeutics, Inc., a biopharmaceutical company specializing in the development of treatments for central nervous system (CNS) disorders, has announced its participation in Sleep Europe 2024, the 27th Congress of the European Sleep Research Society. The event takes place from September 24-27, 2024, in Seville, Spain. Axsome Therapeutics will present seven studies on AXS-12 and solriamfetol, showcasing their ongoing commitment to improving therapies for sleep disorders.

Among the featured presentations, the SYMPHONY Phase 3 trial results of AXS-12 in treating narcolepsy will be highlighted. Additionally, the CRESCENDO patient survey will emphasize the unmet needs of patients with type 1 narcolepsy. Data on solriamfetol will also be discussed, particularly its efficacy in enhancing cognitive function in patients suffering from excessive daytime sleepiness (EDS) due to obstructive sleep apnea (OSA) and narcolepsy.

**AXS-12 Presentations:**

1. **Title:** AXS-12 for the Treatment of Narcolepsy: Topline Results from the Phase 3 SYMPHONY Trial
- **Type:** Poster Presentation
- **Date & Time:** Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CEST
- **Lead Author:** Dr. Michael Thorpy, Director of the Sleep-Wake Disorders Center at Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, USA
- **Poster Number:** P254

2. **Title:** CRESCENDO: Results from a Survey of Symptom Burden and Quality of Life in Patients with Narcolepsy Type 1
- **Type:** Poster Presentation
- **Date & Time:** Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CEST
- **Lead Author:** Dr. Michael Thorpy
- **Poster Number:** P265

**Solriamfetol Presentations:**

1. **Title:** Solriamfetol and Maintenance of Wakefulness Outcomes in Patients with Narcolepsy and Obstructive Sleep Apnea
- **Type:** Oral Presentation
- **Date & Time:** Tuesday, September 24, 9:55 - 10:01 a.m. CEST
- **Poster Presentation Date & Time:** Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CEST
- **Lead Author:** Dr. Michael Thorpy
- **Poster Number:** P475

2. **Title:** Effects of Solriamfetol on Cognition in Patients with Excessive Daytime Sleepiness Associated with Narcolepsy
- **Type:** Poster Presentation
- **Date & Time:** Wednesday, September 25, 12:15 - 1:15 p.m. and 4:00 - 5:45 p.m. CEST
- **Lead Author:** Dr. Yaroslav Winter, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany
- **Poster Number:** P197

3. **Title:** Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression
- **Type:** Poster Presentation
- **Date & Time:** Friday, September 27, 10:45 a.m. - 1:30 p.m. CEST
- **Lead Author:** Dr. Yaroslav Winter
- **Poster Number:** P198

4. **Title:** SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcome
- **Type:** Poster Presentation
- **Date & Time:** Thursday, September 26, 12:00 - 1:30 p.m. and 5:30 - 6:45 p.m. CEST
- **Lead Author:** Dr. Samantha Floam, Axsome Therapeutics
- **Poster Number:** P799

5. **Title:** Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition
- **Type:** Poster Presentation
- **Date & Time:** Friday, September 27, 10:45 a.m. - 1:30 p.m. CEST
- **Lead Author:** Dr. Hans Van Dongen, Professor at Washington State University
- **Poster Number:** P1248

Axsome Therapeutics aims to transform the treatment landscape for CNS disorders through the development of innovative therapies. Their focus remains on providing new therapeutic options that offer significant improvements in patient outcomes.